Studies and publications
A range of studies have demonstrated the superior performance of Respimat® SMI when compared to conventional inhalers, clinical efficacy and good patient acceptance. Please visit the following sections to access summaries of abstracts and publications on these subjects and do not hesitate to order printed copies for free.
The performance of Respimat® SMI
A range of studies has shown superior cloud properties and lung deposition of Respimat® SMI compared to conventional inhalers.
Brand P et al.
Higher Lung Deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD Patients with Poor Technique.
Int J Chronic Obstruct Pulm Dis, Vol 3, Nr. 4, 2008,
Pp 763-770
Clinical studies
Clinical trials have proven the effectiveness of Respimat® SMI at lower dose compared to pMDIs in COPD patients, adult and paediatric patients.
Feifel U et al.
Pharmacokinetics and Tolerability (Study I) with Particular Reference to Ocular Safety (Study 2) of Tiotropium Respimat® Soft Mist™ Inhaler: Findings from Two Dose-ranging Studies in Healthy Men.
Int J Chronic Obstruct Pulm Dis, Vol 3, Nr. 3, 2008,
Pp 397-403
The patient preference
Respimat® SMI is preferred by patients compared to other inhalers.
Hodder R et al.
Asthma Patients Prefer Respimat ® Soft Mist™ Inhaler to Turbohaler®.
Int J Chronic Obstruct Pulm Dis, Vol 4, 2009, Pp225-232
